PrEPVacc HIV vaccine trial shows no reduction in infections

FHS
July 23, 2024
1:01 pm

The results of the PrEPVacc HIV vaccine trial conducted in Eastern and Southern Africa, which ran between 2020 and 2024, show conclusively that neither of the two experimental vaccine regimens tested reduced HIV infections among the study population.

Excessive diet soft drink consumption is associated with the occurrence of liver disease

The association between diet soft drink intake and metabolic dysfunction-associated steatotic liver disease (MASLD).

November 22, 2023

QUT team receives US funding to develop Parkinson’s treatment

The team developing treatments for Parkinson’s disease by targeting the gut microbiome and gut-brain axis. Credit: Queensland University of Technology. Scientists of Queensland University of

May 28, 2024

Extended P2Y12 inhibitor monotherapy reduces bleeding and ischemic events in ACS patients

Extended P2Y12 inhibitor monotherapy beyond 12 months after percutaneous coronary intervention (PCI) reduces bleeding and ischemic events in acute coronary syndrome (ACS) patients at high

August 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.